215 related articles for article (PubMed ID: 32439159)
1. Liver-selective γ-secretase inhibition ameliorates diet-induced hepatic steatosis, dyslipidemia and atherosclerosis.
Kim K; Yu J; Kang JK; Morrow JP; Pajvani UB
Biochem Biophys Res Commun; 2020 Jul; 527(4):979-984. PubMed ID: 32439159
[TBL] [Abstract][Full Text] [Related]
2. γ-Secretase Inhibition Lowers Plasma Triglyceride-Rich Lipoproteins by Stabilizing the LDL Receptor.
Kim K; Goldberg IJ; Graham MJ; Sundaram M; Bertaggia E; Lee SX; Qiang L; Haeusler RA; Metzger D; Chambon P; Yao Z; Ginsberg HN; Pajvani UB
Cell Metab; 2018 Apr; 27(4):816-827.e4. PubMed ID: 29576536
[TBL] [Abstract][Full Text] [Related]
3. Inhibition of Atherosclerosis and Liver Steatosis by Agmatine in Western Diet-Fed apoE-Knockout Mice Is Associated with Decrease in Hepatic De Novo Lipogenesis and Reduction in Plasma Triglyceride/High-Density Lipoprotein Cholesterol Ratio.
Wiśniewska A; Stachowicz A; Kuś K; Ulatowska-Białas M; Totoń-Żurańska J; Kiepura A; Stachyra K; Suski M; Gajda M; Jawień J; Olszanecki R
Int J Mol Sci; 2021 Oct; 22(19):. PubMed ID: 34639029
[TBL] [Abstract][Full Text] [Related]
4. Sterol carrier protein-2 deficiency attenuates diet-induced dyslipidemia and atherosclerosis in mice.
He H; Wang J; Yannie PJ; Kakiyama G; Korzun WJ; Ghosh S
J Biol Chem; 2018 Jun; 293(24):9223-9231. PubMed ID: 29700117
[TBL] [Abstract][Full Text] [Related]
5. Naringenin decreases progression of atherosclerosis by improving dyslipidemia in high-fat-fed low-density lipoprotein receptor-null mice.
Mulvihill EE; Assini JM; Sutherland BG; DiMattia AS; Khami M; Koppes JB; Sawyez CG; Whitman SC; Huff MW
Arterioscler Thromb Vasc Biol; 2010 Apr; 30(4):742-8. PubMed ID: 20110573
[TBL] [Abstract][Full Text] [Related]
6. Effects of antisense-mediated inhibition of 11β-hydroxysteroid dehydrogenase type 1 on hepatic lipid metabolism.
Li G; Hernandez-Ono A; Crooke RM; Graham MJ; Ginsberg HN
J Lipid Res; 2011 May; 52(5):971-81. PubMed ID: 21364201
[TBL] [Abstract][Full Text] [Related]
7. Atherosclerotic dyslipidemia revealed by plasma lipidomics on ApoE
Chen Y; Wen S; Jiang M; Zhu Y; Ding L; Shi H; Dong P; Yang J; Yang Y
Atherosclerosis; 2017 Jul; 262():78-86. PubMed ID: 28527370
[TBL] [Abstract][Full Text] [Related]
8. Prevention of Diet-Induced Metabolic Dysregulation, Inflammation, and Atherosclerosis in
Samsoondar JP; Burke AC; Sutherland BG; Telford DE; Sawyez CG; Edwards JY; Pinkosky SL; Newton RS; Huff MW
Arterioscler Thromb Vasc Biol; 2017 Apr; 37(4):647-656. PubMed ID: 28153881
[TBL] [Abstract][Full Text] [Related]
9. Fucoidan alleviates high-fat diet-induced dyslipidemia and atherosclerosis in ApoE(shl) mice deficient in apolipoprotein E expression.
Yokota T; Nomura K; Nagashima M; Kamimura N
J Nutr Biochem; 2016 Jun; 32():46-54. PubMed ID: 27142736
[TBL] [Abstract][Full Text] [Related]
10. Ces3/TGH deficiency improves dyslipidemia and reduces atherosclerosis in Ldlr(-/-) mice.
Lian J; Quiroga AD; Li L; Lehner R
Circ Res; 2012 Sep; 111(8):982-90. PubMed ID: 22872154
[TBL] [Abstract][Full Text] [Related]
11. Salusin-α attenuates hepatic steatosis and atherosclerosis in high fat diet-fed low density lipoprotein receptor deficient mice.
Tang K; Wang F; Zeng Y; Chen X; Xu X
Eur J Pharmacol; 2018 Jul; 830():76-86. PubMed ID: 29704496
[TBL] [Abstract][Full Text] [Related]
12. Hepatocyte sortilin 1 knockout and treatment with a sortilin 1 inhibitor reduced plasma cholesterol in Western diet-fed mice.
Chen C; Li J; Matye DJ; Wang Y; Li T
J Lipid Res; 2019 Mar; 60(3):539-549. PubMed ID: 30670473
[TBL] [Abstract][Full Text] [Related]
13. Evidence of extensive atherosclerosis, coronary artery disease and myocardial infarction in the ApoE
Venegas-Pino DE; Lagrotteria A; Wang PW; Morphet J; Clapdorp C; Shi Y; Werstuck GH
Atherosclerosis; 2018 Aug; 275():88-96. PubMed ID: 29879686
[TBL] [Abstract][Full Text] [Related]
14. Curcumin modulation of high fat diet-induced atherosclerosis and steatohepatosis in LDL receptor deficient mice.
Hasan ST; Zingg JM; Kwan P; Noble T; Smith D; Meydani M
Atherosclerosis; 2014 Jan; 232(1):40-51. PubMed ID: 24401215
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of PRMT3 activity reduces hepatic steatosis without altering atherosclerosis susceptibility in apoE knockout mice.
Hoekstra M; Nahon JE; de Jong LM; Kröner MJ; de Leeuw LR; Van Eck M
Biochim Biophys Acta Mol Basis Dis; 2019 Jun; 1865(6):1402-1409. PubMed ID: 30776415
[TBL] [Abstract][Full Text] [Related]
16. Antisense oligonucleotide reduction of DGAT2 expression improves hepatic steatosis and hyperlipidemia in obese mice.
Yu XX; Murray SF; Pandey SK; Booten SL; Bao D; Song XZ; Kelly S; Chen S; McKay R; Monia BP; Bhanot S
Hepatology; 2005 Aug; 42(2):362-71. PubMed ID: 16001399
[TBL] [Abstract][Full Text] [Related]
17. Dietary phosphate restriction induces hepatic lipid accumulation through dysregulation of cholesterol metabolism in mice.
Tanaka S; Yamamoto H; Nakahashi O; Kagawa T; Ishiguro M; Masuda M; Kozai M; Ikeda S; Taketani Y; Takeda E
Nutr Res; 2013 Jul; 33(7):586-93. PubMed ID: 23827134
[TBL] [Abstract][Full Text] [Related]
18. Obesity potentiates development of fatty liver and insulin resistance, but not atherosclerosis, in high-fat diet-fed agouti LDLR-deficient mice.
Coenen KR; Hasty AH
Am J Physiol Endocrinol Metab; 2007 Aug; 293(2):E492-9. PubMed ID: 17566116
[TBL] [Abstract][Full Text] [Related]
19. PRMT3 inhibitor SGC707 reduces triglyceride levels and induces pruritus in Western-type diet-fed LDL receptor knockout mice.
de Jong LM; Zhang Z; den Hartog Y; Sijsenaar TJP; Martins Cardoso R; Manson ML; Hankemeier T; Lindenburg PW; Salvatori DCF; Van Eck M; Hoekstra M
Sci Rep; 2022 Jan; 12(1):483. PubMed ID: 35013582
[TBL] [Abstract][Full Text] [Related]
20. Inhibiting monoacylglycerol acyltransferase 1 ameliorates hepatic metabolic abnormalities but not inflammation and injury in mice.
Soufi N; Hall AM; Chen Z; Yoshino J; Collier SL; Mathews JC; Brunt EM; Albert CJ; Graham MJ; Ford DA; Finck BN
J Biol Chem; 2014 Oct; 289(43):30177-88. PubMed ID: 25213859
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
